Every year, Sri Lanka logs 8,500 to 9,500 fresh tuberculosis infections, predominantly in the bustling streets of Colombo, according to the National Programme for Tuberculosis Control. Last year saw 8,726 diagnoses, where 75% involved lung infections and 5,500 patients were highly contagious, posing risks to surrounding communities.
Western regions dominate statistics at 45%, with Colombo’s overcrowded neighborhoods—Modara, Mattakuliya, Borella, Wanathamulla, and Grandpass—emerging as epicenters. A doctor briefed reporters on optimistic projections: roughly 500 fewer cases expected in the coming year, driven by proactive health measures.
This bacterial scourge thrives in air, hitching rides on droplets from infected coughs or sneezes, mainly assaulting respiratory systems. Latent carriers, numbering one in four worldwide, rarely fall ill or spread it. Active TB strikes 5-10%, deadlier in kids without prompt antibiotic therapy. The BCG vaccine stands as a frontline defense for the young, slashing severe outcomes and deaths.
Authorities emphasize vigilance in high-density zones, promoting sputum tests, DOTS therapy, and ventilation improvements. As Sri Lanka urbanizes rapidly, integrating TB control into routine healthcare could transform this manageable menace into a controlled footnote, ensuring healthier futures for its most vulnerable populations.